Allergan Pitches Cost-Cutting Plan In Continued Defense Of Valeant Bid
This article was originally published in The Pink Sheet Daily
Executive Summary
Allergan continued to fend off Valeant during its second quarter earnings call by announcing a plan to save $475 million over the next five years, which includes 1,500 job cuts. Valeant bit back by complaining to the SEC.
You may also be interested in...
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
Update: Ziopharm Study Death Not Due To Drug
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.